Pipeline
At GSK, our pipeline is focused on unlocking the science of the immune system, human genetics, and advanced technologies to develop vaccines and specialty medicines.
Our products in development progress through three stages: phase I, phase II, and phase III/registrational. Each of these phases allows us to assess the safety and efficacy of our investigational products to eventually provide data to support applications for regulatory approval.
DISEASE STATES
VCRC-VPPRN EGPA Registry (Observational Study)
VCRC-VPPRN EGPA Registry (Observational Study)
Anti-BLyS (Belimumab)
SABLE: Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry
Anti-BLyS (Belimumab)
SABLE: Safety and Effectiveness of Belimumab in Systemic Lupus Erythematosus Registry
A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE) (BE-EARLY)
A Study of the Efficiency And Safety Study of Belimumab Compared To Placebo In Adults With Systemic Sclerosis Associated Interstitial Lung Disease (BLISSc-ILD)
A Study of the Efficiency And Safety Study of Belimumab Compared To Placebo In Adults With Systemic Sclerosis Associated Interstitial Lung Disease (BLISSc-ILD)
0 results - Use filter to search Pipeline